文献速递脑血管病

替奈普酶与阿替普酶治疗远端及中等血管闭塞的早期再通比较

Early Recanalization After Tenecteplase or Alteplase in Distal and Medium Vessel Occlusion Strokes: An Observational Cohort Study
RSS 订阅 · Stroke

本研究为单中心观察性队列研究,纳入法国 Centre Hospitalier Sud-Francilien 经 MRI 证实的远端及中等血管闭塞卒中患者,比较替奈普酶与阿替普酶静脉溶栓后的早期再通。结果显示替奈普酶组早期成功再通率更高,且早期梗死显著增长风险更低。

要点

  • 替奈普酶组早期成功再通率为45.3%,高于阿替普酶组33.1%。
  • 替奈普酶组早期梗死显著增长发生率为26.8%,低于阿替普酶组40.5%。
  • 倾向评分加权后替奈普酶与更高早期成功再通及更低梗死增长风险相关。

核心结论

  • 与阿替普酶相比,替奈普酶治疗的远端及中等血管闭塞患者早期成功再通率更高,早期梗死显著增长风险更低。

研究设计与样本

  • 单中心观察性队列研究,纳入 MRI 证实的远端及中等血管闭塞卒中患者。
  • 按机构溶栓方案,阿替普酶组使用0.9 mg/kg,替奈普酶组使用0.25 mg/kg。
  • 静脉溶栓后1至2小时进行随访MRI,排除拟行血管内取栓或随访MRI质量不合格者。

主要发现

  • 319例患者中替奈普酶组159例,阿替普酶组160例;基线NIHSS中位数分别为3(1–7)和4(1–7.5)。
  • M2闭塞在替奈普酶组占54.1%,在阿替普酶组占43.8%。
  • 静脉溶栓后中位80(70–94)分钟评估,替奈普酶组早期成功再通72例(45.3%),阿替普酶组53例(33.1%)。
  • 倾向评分加权后早期成功再通的比值比为1.59(95%CI,1.15–2.20;P=0.005)。
  • 早期梗死显著增长在替奈普酶组42例(26.8%),阿替普酶组64例(40.5%),加权比值比为0.49(95%CI,0.35–0.69;P<0.0001)。

关键数值与推荐

  • 早期成功再通定义为早期随访MRI上再通≥50%(分级≥2b)。
  • 早期梗死显著增长定义为病灶体积增加≥0.5 mL且≥20%。
  • 再通评估采用针对MRI和远端及中等血管闭塞改良的Arterial Occlusion Lesion量表。

临床怎么用

  • 研究结果支持在远端及中等血管闭塞卒中中优先使用替奈普酶进行静脉溶栓。

局限性

  • 本研究为单中心观察性队列设计,存在残余混杂可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Stroke, Ahead of Print. BACKGROUND:Intravenous thrombolysis remains the standard treatment for distal and medium vessel occlusion (DMVO) strokes. However, unlike large vessel occlusions, whether tenecteplase achieves higher early successful recanalization rates than alteplase in DMVO strokes remains uncertain.METHODS:This single-center observational cohort study included consecutive patients with magnetic resonance imaging (MRI)-confirmed DMVO stroke treated at Centre Hospitalier Sud-Francilien, France, according to an institutional thrombolysis protocol specifying alteplase (0.9 mg/kg, 2016–2018) or tenecteplase (0.25 mg/kg, 2018–2023), with follow-up MRI 1 to 2 hours after intravenous thrombolysis. Patients intended for endovascular thrombectomy or without diagnostic-quality follow-up MRI were excluded. Recanalization was blindly assessed using a modified Arterial Occlusion Lesion scale designed for MRI and DMVO. Early successful recanalization was defined as ≥50% recanalization on early follow-up MRI (grade ≥2b), and substantial early infarct growth, assessed using a semiautomatic segmentation technique, was defined as a ≥0.5 mL and ≥20% increase in lesion volume. Propensity-score weighting accounted for baseline imbalances, including age, sex, vascular risk factors, baseline National Institutes of Health Stroke Scale score, occlusion site, and time period (2020–2023 versus 2016–2019).RESULTS:Of the 319 included patients, 159 were treated with tenecteplase and 160 with alteplase. Median baseline National Institutes of Health Stroke Scale was 3 (1–7) in the tenecteplase group versus 4 (1–7.5) in the alteplase group, while M2 occlusions accounted for 54.1% versus 43.8% of cases. Early successful recanalization, assessed at a median postintravenous thrombolysis time of 80 (70–94) minutes, occurred in 72 (45.3%) and 53 (33.1%) patients treated with tenecteplase and alteplase, respectively (propensity-score weighting–odds ratio, 1.59 [95% CI, 1.15–2.20];P=0.005). Substantial early infarct growth was observed in 42 (26.8%) and 64 (40.5%) patients, respectively (propensity-score weighting–odds ratio, 0.49 [95% CI, 0.35–0.69];P<0.0001).CONCLUSIONS:Compared with alteplase, tenecteplase-treated patients with DMVO had higher early successful recanalization and a lower risk of substantial early infarct growth, supporting its preferential use in this setting.REGISTRATION:URL:https://www.clinicaltrials.gov; Unique identifier: NCT05635786.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Stroke:Early Recanalization After Tenecteplase or Alteplase in Distal and Medium Vessel Occlusion Strokes: An Observational Cohort Study

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。